HEMODYNAMIC EFFECTS AND CARDIOVASCULAR SAFETY OF ONCE-DAILY ORAL AMPRELOXETINE (TD-9855), A NOREPINEPHRINE REUPTAKE INHIBITOR, IN HEALTHY ADULTS AND SUBJECTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION

Inadequate release of norepinephrine (NE) in neurogenic orthostatic hypotension (nOH) patients causes blood pressure (BP) drops on standing and debilitating symptoms of cerebral hypoperfusion. Ampreloxetine is a novel longer-acting NE reuptake inhibitor that potentiates the release of endogenous NE